LA JOLLA PHARMACEUTICAL CO Form 8-K July 22, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 22, 2014

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

California (State or other jurisdiction of incorporation or organization) 1-36282 (Commission File Number) 33-0361285 (I.R.S. Employer Identification No.)

4660 La Jolla Village Drive, Suite 1070, San Diego, California 92122 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (858) 207-4264

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act
- o (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
- O (17 CFR 240.14d-2(b))
 Due source state and the sector state and t
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

Item 8.01 Other Events.

Attached hereto as Exhibit 99.1 is a corporate presentation regarding La Jolla Pharmaceutical Company's product pipeline as of July 2014.

Item 9.01 Financial Statements and Exhibits (d) Exhibits.

Exhibit
No.Description99.1Presentation regarding La Jolla Pharmaceutical Company's product pipeline as of July 2014.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: July 22, 2014

By: /s/ George F. Tidmarsh

Name: George F. Tidmarsh, M.D., Ph.D. Title: President and Chief Executive Officer